Objective To evaluate the safety of batroxobin (defibrating therapy) in the treatment of sudden hearing loss in the elderly patients by detecting serum level of fibrinogen (FIB). Methods A total of 111 patients suffering from hearing loss or tinnitus admitted in the Department of Rehabilitation of our hospital from January to December 2014 were recruited in this study. They were divided into 2 groups according to their age, the elderly group (age ≥60 years) and the young and middle-aged group (aged from 20 to 59 years). Both of them received 10BU batroxobin on day 1 (if the patient was older than 70 years, the dose was 5BU) and other conventional therapies. The blood level of FIB was tested before, and at 1st or 2nd day after batroxobin treatment. Their systematic bleeding was also observed. Results At the beginning of the treatment, there was no difference in the FIB level between the elderly and young and middle-aged groups [(302.38±53.08) vs (297.13±97.62)mg/dl, P＝0.812]. During the treatment, no difference was seen in FIB level and decline of FIB between the 2 groups. The incidence of crisis on the 4th day was obviously higher in the elderly group than in the young and middle-aged group, but no such difference was seen at other time points. Conclusion There is no difference in the safety of batroxobin in treatment of sudden hearing loss between the elderly and young and middle-aged patients.